Journey Medical (DERM) Projected to Post Earnings on Wednesday

Journey Medical (NASDAQ:DERM) is projected to post its Q4 2025 results after the market closes on Wednesday, March 25th. Analysts expect Journey Medical to post earnings of ($0.06) per share and revenue of $18.8630 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 4:30 PM ET.

Journey Medical Stock Performance

NASDAQ:DERM opened at $6.90 on Tuesday. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.42 and a quick ratio of 1.12. The firm has a market cap of $229.47 million, a PE ratio of -19.71 and a beta of 0.81. The firm has a 50 day simple moving average of $8.11 and a 200-day simple moving average of $7.83. Journey Medical has a 1-year low of $5.51 and a 1-year high of $9.56.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Journey Medical in a report on Wednesday, January 21st. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Journey Medical has a consensus rating of “Hold” and a consensus price target of $12.17.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Bank of America Corp DE lifted its holdings in shares of Journey Medical by 4,707.0% during the 2nd quarter. Bank of America Corp DE now owns 4,134 shares of the company’s stock worth $30,000 after acquiring an additional 4,048 shares during the period. Raymond James Financial Inc. purchased a new stake in Journey Medical in the second quarter valued at approximately $36,000. JPMorgan Chase & Co. acquired a new position in Journey Medical during the second quarter worth approximately $41,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Journey Medical during the second quarter worth approximately $48,000. Finally, Russell Investments Group Ltd. purchased a new position in Journey Medical during the third quarter worth approximately $61,000. Institutional investors and hedge funds own 7.25% of the company’s stock.

Journey Medical Company Profile

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.